DKSH, the leading Market Expansion Services provider with a focus on Asia, and AFT Pharmaceuticals Limited, an Australasian pharmaceutical company, have partnered to introduce the first combination drug of paracetamol and ibuprofen called Maxigesic in Hong Kong.
Media release
Hong Kong, December 20, 2018 – DKSH Hong Kong, the leading Market Expansion Services provider for companies seeking to grow their business, has started its partnership with AFT Pharmaceuticals Limited. The Australasian pharmaceutical company develops, licenses and sells a range of medical products globally. DKSH will bring its unique combination drug Maxigesic to patients in Hong Kong and Macau by providing full agency services, which include product registration, marketing and sales as well as distribution and logistics in both Hong Kong and Macau.
Maxigesic is the first combination drug of paracetamol and ibuprofen in the local markets. It provides double-action pain relief without codeine. DKSH targets to bring this product to market through local healthcare professionals with distribution points at hospitals, clinics and pharmacies. DKSH has been working steadfastly with AFT Pharmaceuticals to register Maxigesic in Hong Kong. The product registration is completed, with sales starting now.
“We are delighted to work with AFT Pharmaceuticals and support them in bringing the first combination drug to Hong Kong and Macau,” commented Grace Lau, Head, Management, Hong Kong, DKSH Hong Kong. “This kind of innovative medicine allows patients to achieve better and faster pain relief. We are thrilled to work with another multinational pharmaceutical company that brings real innovation to patients' lives.”
“We are impressed by the in-depth market knowledge and extensive distribution network of DKSH. They supported us with the product registration and we are convinced that they will provide the same professionalism in sales promotion and local distribution,” said Dr. Hartley Atkinson, CEO and Founder of AFT Pharmaceuticals Limited. “We are looking forward to partnering with DKSH to further innovate the analgesic sector in Hong Kong and Macau.”
For further information please contact:
DKSH Hong Kong Limited
Amy Tam
Branding and Communications Manager
Hong Kong and China
Phone +852 2895 9610
amy.tam@dksh.com
About AFT Pharmaceuticals Limited
AFT Pharmaceuticals, listed on the NZX and ASX are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories. Their products are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.
About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets. Publicly listed on the SIX Swiss Exchange since 2012, DKSH is a global company headquartered in Zurich. With 825 business locations in 37 markets – 800 of them in Asia – and 31,970 specialized staff, DKSH generated net sales of CHF 11.0 billion in 2017. DKSH was founded in 1865. With strong Swiss heritage, the company has a long tradition of doing business in and with Asia and is deeply rooted in communities and businesses across Asia Pacific.
DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration, regulatory services, market entry studies, importation, customs clearance, marketing and sales, capillary physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With 130 business locations in 14 markets and around 9,370 specialized staff, Business Unit Healthcare serves over 150,000 customers and generated net sales of CHF 6.1 billion in 2017.